You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Researchers found that more than 3 percent of postmenopausal women with breast cancer but no other disease risk factors carried pathogenic variants.
Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.
The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
Stanford University's Allison Kurian and her colleagues found that women with pathogenic variants were more likely to undergo a bilateral mastectomy.
The test is designed to determine breast cancer risk by analyzing a number of factors including breast density, breast biopsy history, and a polygenic score.
If cancer patients carrying the variants could be identified early, their therapeutic strategy could be altered to reduce their risk of cardiomyopathy.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.